Oxford, United Kingdom
Refeyn is a transformative player in the Biotechnology and Life Sciences sectors, hailing from the United Kingdom. Founded in 2018, the company is at the forefront of molecular analysis through its pioneering mass photometry technology. This innovative approach offers a novel way of weighing individual molecules using light, facilitating rapid and direct insights into biomolecular functions and structures.
The technology provided by Refeyn is particularly influential in accelerating biotherapeutic development, underscored by over 1200 academic citations and 600 global installations. Notably, their instruments have been utilized in research that has achieved the prestigious Nobel Prize, indicating a strong validation and endorsement from the scientific community.
With a significant $30.00M Series A investment from Northpond Ventures in November 2020, Refeyn is well-positioned to continue its trajectory of innovation and impact, driving forward the next era of scientific discovery and bioanalytic advancements.
